Companies: Hengrui Pharma, Kailera Therapeutics
Drugs: ribupatide
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Data at ADA 2026
100% citation coverage1 regulatory sources
Hengrui Pharma and Kailera Therapeutics presented clinical data for oral ribupatide (HRS9531) at the ADA 2026 conference. The Phase 2 trial showed positive weight loss results, and the partners plan to advance the asset into two new trials.
Intelligence Snapshot
Executive Summary
Hengrui Pharma and Kailera Therapeutics presented Phase 2 data for oral ribupatide (HRS9531) at the American Diabetes Association 86th Scientific Sessions (ADA 2026).
Key Insights
-
The trial showed positive weight loss results in adults with obesity, supporting…
The trial showed positive weight loss results in adults with obesity, supporting advancement into two new clinical trials.
-
Ribupatide is a once-daily oral GLP-1 receptor agonist, positioning it as a potential…
Ribupatide is a once-daily oral GLP-1 receptor agonist, positioning it as a potential competitor to oral semaglutide and orforglipron in a high-stakes obesity pipeline.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | high |
| Investment | medium |
Loading intelligence…
Quick Answer
Hengrui Pharma and Kailera Therapeutics presented Phase 2 data for oral ribupatide (HRS9531) at the American Diabetes Association 86th Scientific Sessions (ADA 2026).
Key Questions
- What is ribupatide?
- Who is developing ribupatide?
- What data were presented at ADA 2026?
- What are the next steps for ribupatide?
- How does ribupatide compare to other oral GLP-1 drugs?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for ribupatide.
Unlock full calendar →Contents7 sections
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Data at ADA 2026
Hengrui Pharma and Kailera Therapeutics presented clinical data for oral ribupatide (HRS9531) at the ADA 2026 conference. The Phase 2 trial showed positive weight loss results, and the partners plan to advance the asset into two new trials, reinforcing the competitive trajectory of oral GLP-1 receptor agonists in the obesity market.
IntelligenceRegulatory Impact
FDA and EMA decisions frame this story. Regulatory relevance is medium for GLP-1, with ribupatide most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
Key Takeaways
- Hengrui Pharma and Kailera Therapeutics presented Phase 2 data for oral ribupatide (HRS9531) at the American Diabetes Association 86th Scientific Sessions (ADA 2026).
- The trial showed positive weight loss results in adults with obesity, supporting advancement into two new clinical trials.
- Ribupatide is a once-daily oral GLP-1 receptor agonist, positioning it as a potential competitor to oral semaglutide and orforglipron in a high-stakes obesity pipeline.
IntelligenceCompetitive Intelligence
Competitive pressure is high. Hengrui Pharma and Kailera Therapeutics reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.
The Development
On June 5, 2026, Hengrui Pharma and Kailera Therapeutics announced the presentation of clinical data for oral ribupatide at the ADA 2026 conference. Hengrui presented data from its Phase 2 clinical trial of oral ribupatide in adults living with obesity, while Kailera presented additional clinical data from its own studies. The companies had previously reported positive topline weight loss results from the Phase 2 trial, which underpinned the decision to move forward. The specific weight loss percentage, confidence intervals, and p-values from the Phase 2 trial have not been disclosed in the public release, but the topline readout was sufficient to trigger advancement plans.
Ribupatide, also known as the HRS9531 tablet, is a once-daily oral GLP-1 receptor agonist. Kailera Therapeutics, based in Waltham, Massachusetts, serves as the US development partner, while Hengrui Pharma is the China-based originator and co-developer. The partnership model—a China-originated asset paired with a US-based biotech—has become a familiar structure for cross-border obesity deals. A search of ClinicalTrials.gov does not currently list a registered trial for ribupatide, suggesting the Phase 2 program may have been conducted under a non-US registry or under a different identifier.
IntelligenceMarket Signals
Commercial pull is medium and investment relevance medium for GLP-1. Expect implications for pricing, access, and launch sequencing.
Implications for Pharma Teams
For BD teams and analysts, the ADA 2026 data reinforces ribupatide’s potential as an oral GLP-1 competitor in the obesity market. The positive Phase 2 weight loss results and the planned advancement into two new trials signal a maturing pipeline that warrants close tracking. The Hengrui-Kailera partnership model is a template for cross-border deals, particularly for assets originating in China and requiring US clinical and regulatory infrastructure.
Teams should compare ribupatide’s efficacy and tolerability profile against other oral GLP-1s—such as oral semaglutide and orforglipron—and watch for differentiation in dosing, adherence, or side effects. The next catalysts are the initiation of the two new clinical trials and any regulatory engagement with the FDA or NMPA. For investors, the key question is whether ribupatide can match or exceed the weight loss seen with injectable GLP-1s while maintaining the convenience of an oral formulation. The FDA’s precedent with oral semaglutide provides a regulatory benchmark for the oral GLP-1 class, though ribupatide’s specific development path may differ.
Frequently Asked Questions
What is ribupatide?
Ribupatide (HRS9531) is a once-daily oral GLP-1 receptor agonist being developed for obesity and potentially other metabolic conditions. It is a small-molecule GLP-1 agonist designed for oral administration, differentiating it from injectable competitors.
Who is developing ribupatide?
Ribupatide is being co-developed by Hengrui Pharma, based in China, and Kailera Therapeutics, based in Waltham, Massachusetts. Hengrui originated the asset and leads development in China, while Kailera is responsible for US development and regulatory strategy.
What data were presented at ADA 2026?
Hengrui Pharma presented Phase 2 data from a trial of oral ribupatide in adults with obesity, and Kailera Therapeutics presented additional clinical data. The companies had previously announced positive topline weight loss results from the Phase 2 trial, which supported the decision to advance the asset into two new clinical trials.
What are the next steps for ribupatide?
The partners plan to initiate two new clinical trials for oral ribupatide. The specific trial designs have not been disclosed, but they are expected to include larger efficacy and safety studies that could support registration filings with the FDA and NMPA.
How does ribupatide compare to other oral GLP-1 drugs?
Ribupatide competes in the oral GLP-1 class alongside oral semaglutide (Novo Nordisk) and orforglipron (Eli Lilly). Key differentiators will include weight loss magnitude, tolerability, dosing frequency, and the ability to match injectable efficacy with oral convenience. Comparative data are not yet available from head-to-head trials.
IntelligenceStrategic Takeaways
Hengrui Pharma and Kailera Therapeutics presented Phase 2 data for oral ribupatide (HRS9531) at the American Diabetes Association 86th Scientific Sessions (ADA 2026). The trial showed positive weight loss results in adults with obesity, supporting advancement into two new clinical trials. Ribupatide is a once-daily oral GLP-1 receptor agonist, positioning it as a potential competitor to oral semaglutide and orforglip
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About GLP-1
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow ribupatide developments
NMPA glp-1 alerts and ribupatide pipeline updates, every Monday.
- Sources analyzed
- 1
- Evidence strength
- 81/100
- Last verified
- Jun 6, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
High source quality · grounded in cited primary and secondary sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
About the Author
Continue Your Research
Industry Reports & Whitepapers
- Ensuring Compatibility for GLP-1-based Drugs — The rise of GLP-1 agonists like Semaglutide demands innovative ready-to-use cartridges to enhance de…
- Lilly's Weight-Loss Pill Approved, Sparking Competition with Novo Nordisk — Eli Lilly's daily weight-loss pill received FDA approval, setting the stage for a competitive battle…